Bioheart, Inc. company was founded in 1999 and is headquartered in Sunrise, Florida. Bioheart, Inc. is a biotechnology company focused on the discovery, development and subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic acute heart damage and peripheral vascular disease. MyoCell is a clinical therapy designed to populate regions of scar tissue within a patient’s heart with living cells for the purpose of improving cardiac function in chronic heart failure patients. The Company’s clinical trials of MyoCell include the SEISMIC Trial, a completed 40 patient Phase II clinical trial conducted in Europe, and the MYOHEART Trial, a completed 20 patient, Phase I dose escalation trial conducted in the United States. In its pipeline, the Company has multiple product candidates for the treatment of heart damage, including Bioheart Acute Cell Therapy, an autologous, adipose cell treatment for acute heart damage, and MyoCell SDF-1, a therapy utilizing autologous cells genetically modified to express additional growth proteins.

Epigenomics AG is a Germany-based company engaged in the molecular diagnostics sector. It divides its products into two areas: solutions for early diagnosis of cancer and products for special diagnosis of cancer. Epigenomics AG produces and develops tests that help in the diagnosis of the colorectal, prostate and lung cancer. The Company also offers services in the field of identification and development of methylated deoxyribonucleic acid (DNA) biomarkers. Industry partners and the medical and life science communities can access the Company’s portfolio of filed patent families covering DNA methylation technologies and biomarkers, as well as its DNA methylation expertise through research products, biomarker services, in vitro diagnostics (IVD) development collaborations and licensing. It develops its solutions together with its commercial partners, Abbott Molecular Inc and Quest Diagnostics Inc. The Company has a subsidiary in the United States, Epigenomics, Inc.

ImmunoGen was founded in 1981 and is headquartered in Waltham, Massachusetts. ImmunoGen, Inc. engages in the research and development of antibody-based anticancer therapeutics in the United States. The company develops therapeutics for the treatment of cancer using its Targeted Antibody Payload (TAP) technology, which uses antibodies to deliver a potent cytotoxic agent. Its products include Trastuzumab-DM1, a Phase II clinical trial product for the treatment of metastatic breast cancer; IMGN901, a Phase I clinical trial product to treat hematological malignancies, including multiple myeloma, small-cell lung cancer, Merkel cell carcinoma, and other cancers of neuroendocrine origin; SAR3419, a Phase I clinical trial product for the treatment of B-cell hematological malignancies, including non-Hodgkin's lymphoma; and IMGN388 and BIIB015, which are in Phase I clinical trials for the treatment of solid tumors. The company's products also comprise BT-062, a Phase I clinical trial product targeting multiple myeloma; SAR566658, a preclinical trail product for the treatment of breast, ovarian, and other solid tumors; SAR650984, a preclinical trail product to treat hematological malignancies; and TAP and other compounds. It has licensing or collaboration agreements with sanofi-aventis; Genentech, Inc.; Biotest AG; Bayer HealthCare AG; Biogen Idec; Amgen, Inc.; Centocor, Inc.; Cytovance Biologics LLC; Laureate Pharma, Inc.; BioInvent International AB; Diosynth RTP, Inc.; and Societa Italiana Corticosteroidi S.r.l.

Sucampo Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland. Sucampo Pharmaceuticals, Inc., through its subsidiaries, focuses on the discovery, development, and commercialization of drugs based on prostones in the United States, Europe, and Japan. It offers prostone-based compounds for the treatment of gastrointestinal, vascular, respiratory, and central nervous system diseases and disorders. The company primarily markets Amitiza for the treatment of chronic idiopathic constipation in adults, as well as for irritable bowel syndrome with constipation in adult women. It also offers Rescula (unoprostone isopropyl) for the treatment of glaucoma. In addition, Sucampo Pharmaceuticals is conducting two Phase III pivotal trials of Amitiza for opioid-induced bowel dysfunction; a Phase II proof of concept trial of Cobiprostone for the prevention of non-steroidal anti-inflammatory drug induced ulcers; various preclinical trials of Cobiprostone for cystic fibrosis respiratory symptoms, topical ulcers and wounds, and chronic obstructive pulmonary disease; and a preclinical phase study of SPI-017 for Alzheimer's disease. The company also has various pre-clinical studies of six additional preclinical prostone compounds, including two combination candidates for age-related diseases.

Intercell USA (formerly Iomai) is developing needle-free alternatives to boost your immune system using a transcutaneous method, which delivers vaccines to cells found on the outer layers of the skin. It has a handful of product candidates in development, all in patch form, aimed at preventing seasonal flu and travelers' diarrhea (caused by E. coli, for instance). One of its patches is being funded under a contract from the US Department of Health and Human Services to aid in the treatment of pandemic flu. In 2008 the company was acquired by Austria-based vaccine maker Intercell AG.

454 Life Sciences company has developed a computer-controlled instrument and related software that enable scientists to analyze whole genomes in one fell swoop, rather than a few hundred genes at a time. Parent company Roche Diagnostics distributes 454 Life Sciences' Genome Sequencing Systems to clinical laboratories, research departments of drugmakers, and other customers worldwide. Research fields include cancer and infectious disease, drug discovery, and paleontology. The company's 454 Sequencing Center provides sequencing services directly.

Targeted Genetics is putting the bull's-eye on disease. The drug developer is working in the promising (though as yet unproven) field of gene therapies, drugs that deliver particular DNA sequences into targeted cells to encourage (or sometimes inhibit) the production of proteins associated with disease. The company's drug candidates -- targeting conditions such as retinal dystrophies, lateral sclerosis, HIV/AIDS, heart failure, and Huntington's disease -- employ proprietary technology using bio-engineered viral cells (called vectors) to deliver the genes. The company is working on its own to develop therapies for certain candidates and with development partners on some other programs.

GeoPharma, Inc. was founded in 1985 and is headquartered in Largo, Florida. GeoPharma, Inc. is engaged in manufacturing, packaging and distributing private label dietary supplements, generic drugs, and health and beauty products under six of its companies, Innovative Health Products, Inc., Libi Labs, Belcher Pharmaceuticals, Inc., American Antibiotics, LLC and EZ-Med. Innovative Health Products and Libi Labs specialize in the development and manufacture of a range of nutritional supplements and cosmeceuticals. Its subsidiaries include Belcher Pharmaceuticals, Inc., Go2PBM Services, Inc., IHP Marketing, Inc., Breakthrough Marketing, Inc., Belcher Capital Corporation, American Antibiotics, LLC, Libi Labs, Inc., EZ-Med Company (EZ-Med) and Dynamic Health Products, Inc. Effective March 31, 2009, the Company discontinued its Distribution segment, which includes Breakthrough Engineered Nutrition.

MAP Pharmaceuticals was founded in 2003 and is headquartered in Mountain View, California. MAP Pharmaceuticals, Inc., a development stage company, engages in developing drug candidates to treat local respiratory and treatable diseases primarily in the United States. The company develops inhalable drug particles to facilitate pulmonary delivery. Its proprietary product candidates in clinical development include Unit Dose Budesonide, a nebulized version of budesonide for the treatment of asthma in children; and MAP0004, an orally inhaled version of dihydroergotamine for the treatment of migraine. MAPP company's product portfolio also includes the earlier stage product candidates, which include MAP0005, an inhaled corticosteroid and beta-agonist for the treatment of asthma and chronic obstructive pulmonary disease; and MAP0001, a formulation of insulin for the treatment of Type 1 and Type 2 diabetes through pulmonary delivery using Tempo inhaler. It has a collaborations and license agreements with AstraZeneca, Elan Pharma International, Nektar Therapeutics, and Xemplar Pharmaceuticals.

Schiff Nutrition International, Inc. was founded in 1996 and is headquartered in Salt Lake City, Utah. Schiff Nutrition International, Inc. develops, manufactures, markets and distributes branded and private label vitamins, nutritional supplements and nutrition bars in the United States and throughout the world. The Company offers a range of capsules, tablets and nutrition bars. Its portfolio of brands includes Schiff, Move Free, MegaRed and Tiger’s Milk, which is marketed through the mass market, including club and health food store distribution channels. The Company markets a range of specialty supplements, vitamins and minerals under the Schiff brand. The Schiff brand specialty supplements are designed to provide consumers with targeted support for their wellness efforts. Its specialty supplements include joint care products marketed under the Schiff brand, including its Move Free and Glucosamine products. Its Move Free product is one of the joint care products in the mass market channel.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.